Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC.
Immune checkpoint inhibitors (ICIs) redefined the therapeutics of non-small cell lung cancer (NSCLC), leading to significant survival benefits and unprecedented durable responses. However, the majority of the patients develop...
Read More